Dr. Guilcher is an associate professor of oncology and pediatrics at the University of Calgary. His clinical and research focus is hematopoietic cell transplantation (HCT) for non-malignant diseases. He also studies acute and late effects of oncology and BMT therapies. He serves as the Vice Chair of the Board of Directors and Clinical Operations for the Sickle Transplant Alliance for Research and is the Chair of the HCT Late Effects Taskforce for the Children’s Oncology Group. He is Program Director for Pediatric Hematology / Oncology at the University of Calgary, with a number of postdoctoral fellows at the Royal College of Physicians and Surgeons of Canada and teaches regularly in Mbarara, Uganda.
Or, objectives:
The only known cure for Sickle Cell Disease is a stem cell transplant (or bone marrow transplant). Due to the difficulty in finding an identical match and the significant risks involved in this procedure, including life-threatening complications, it is rarely an option for sickle cell patients.